This website is for UK Healthcare Professionals only

Prescribing information can be accessed by the Prescribing Information button on the left

UK-VNCAML-220171  |  November 2022. 

VENCLYXTO in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.1

Adverse events should be reported.
Reporting forms and information can be found at or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. 

Adverse events should also be reported to AbbVie on [email protected]

Grading Definitions


Grade 1: ANC 1000 to 1500/μL 

Grade 2: ANC 500 to 999/μL 

Grade 3: ANC 200 to 499/μL 

Grade 4: ANC <500/μL 



Grade 1: Platelet count 75,000-150,000/μL

Grade 2: Platelet count 50,000-74,999/μL

Grade 3: Platelet count 25,000-49,999/μL

Grade 4: Platelet count <25,000/μL 

Non-haematological toxicity5

Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated

Grade 2: moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental activities of daily living

Grade 3: severe or medically significant but not immediately life threatening; hospitalisation or prolongation of hospitalisation indicated; disabling; limiting self care activities of daily living

Grade 4: life threatening consequences; urgent intervention indicated



  1. VENCYLXTO Summary of Product Characteristics for UK.
  2. DiNardo CD et al. N Engl J Med. 2020; 383(7): 617-29. 
  3. Newburger PE, Dale DC. Semin Hematol. 2013 Jul;50(3):198-206.
  4. Tamamyan G et al. Crit Rev Oncol Hematol. 2016 Mar;99:299-307.
  5. Non-haematological toxicity. Available at: